437,872 Shares in Kenvue Inc. $KVUE Bought by SEB Asset Management AB

SEB Asset Management AB bought a new position in Kenvue Inc. (NYSE:KVUE) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 437,872 shares of the company’s stock, valued at approximately $7,549,000.

Other institutional investors have also recently bought and sold shares of the company. Swiss National Bank lifted its holdings in shares of Kenvue by 6.9% during the 1st quarter. Swiss National Bank now owns 5,622,946 shares of the company’s stock worth $96,940,000 after acquiring an additional 364,000 shares during the period. Mediolanum International Funds Ltd acquired a new stake in shares of Kenvue during the 1st quarter valued at about $270,000. Ceera Investments LLC increased its stake in Kenvue by 4.4% in the first quarter. Ceera Investments LLC now owns 156,874 shares of the company’s stock valued at $2,705,000 after acquiring an additional 6,625 shares during the period. Heartland Bank & Trust Co increased its stake in Kenvue by 9.2% in the first quarter. Heartland Bank & Trust Co now owns 12,261 shares of the company’s stock valued at $211,000 after acquiring an additional 1,037 shares during the period. Finally, Advisortrust Partners LLC raised its position in Kenvue by 12.8% in the first quarter. Advisortrust Partners LLC now owns 21,277 shares of the company’s stock worth $367,000 after purchasing an additional 2,413 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Down 0.2%

Shares of KVUE opened at $18.98 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The company has a market cap of $36.43 billion, a price-to-earnings ratio of 22.32, a PEG ratio of 1.44 and a beta of 0.47. The stock has a fifty day moving average price of $18.26 and a two-hundred day moving average price of $17.88. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $22.87.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter in the prior year, the business earned $0.24 earnings per share. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. Analysts predict that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were issued a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.4%. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Citigroup cut their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Wall Street Zen upgraded Kenvue to a “buy” rating in a research note on Sunday, July 12th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. UBS Group raised their target price on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, July 16th. Finally, Barclays boosted their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $19.58.

Insider Buying and Selling at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.59% of the stock is currently owned by corporate insiders.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.